Nutriband Inc. has announced amendments to its Articles of Incorporation, as approved by the Board of Directors on July 9, 2025. The company will introduce a new series of non-voting shares of Preferred Stock, known as Series A Convertible Preferred Stock, with a par value of $0.001 per share. A total of 2,788,678 shares of Series A Preferred Stock have been authorized. Additionally, a preferred stock dividend will be issued, granting shareholders one share of Series A Preferred Stock for every four shares of common stock held. The conversion of Series A Preferred Stock into common stock will be possible after the commercial approval of the company's transdermal pharmaceutical products by the FDA.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.